FDA Warning Letters to Drug Manufacturers: A 2008–2026 Analysis
We analysed 335 FDA Warning Letters issued to pharmaceutical and drug manufacturers between 2008–2026. Two patterns stand out: enforcement is heavily concentrated in just two countries, and after a decade-long decline, Warning Letters rebounded sharply in 2025.
Data as of July 2026 · Source: U.S. FDA · Analysis by PharmaTek Intelligence
Key findings
Two countries dominate FDA drug enforcement
Of the 297 Warning Letters with an identified company headquarters, 37% went to US-based firms and 31% to India-based firms — nearly 7 in 10 letters between just two countries. China (7%) was a distant third.
2025 was the sharpest rebound in nearly a decade
After falling to a low of 7 letters in 2021, annual volume doubled the 2022–2024 average (12/yr) to reach 24 in 2025 — the highest single-year total since 2016. Partial-year 2026 (14 through mid-year) is on pace to match it.
Offshore scrutiny is a structural feature, not a blip
India has drawn the second-most Warning Letters every recent year despite manufacturing offshore — a reminder that a low landed cost can carry real regulatory risk that a supplier's brochure will never show.
Warning Letters by year
Annual FDA drug Warning Letters, 2008–2026. 2026 is a partial year (through July 2026).
Highlighted: 2025 (24, most since 2016) and partial 2026.
Warning Letters by company headquarters
Top 10 countries by number of letters (of 297 with an identified HQ; a further 19 span other countries).
Highlighted: India — the #2 source of FDA drug Warning Letters.
What this means for sourcing teams
A Warning Letter is the FDA's formal notice that a manufacturer has significant violations of current Good Manufacturing Practice — often the step before import alerts, consent decrees, or supply disruption. For a buyer, an open or recent Warning Letter at a candidate site is a material risk that no capability deck will surface.
The geography is the practical takeaway. The US and India together account for nearly seven in ten letters, and India's share has held despite — or because of — its central role in global API and generic manufacturing. That doesn't make any single supplier a poor choice; it makes screening the regulatory record a non-negotiable step when you qualify a CDMO or API supplier — alongside an FDA Form 483 history and recall record.
PharmaTek screens its supplier directory against live FDA enforcement data — recalls, Warning Letters, and Form 483 observations — so these signals surface before you engage.
Methodology & sources
- Dataset: 335 FDA Warning Letters classified as drug/pharmaceutical actions and linked to companies in the PharmaTek directory, issued 2008–2026 (2026 partial, through July 2026).
- Source: U.S. Food & Drug Administration compliance actions (openFDA and the FDA Warning Letters archive). Geography is the manufacturer's headquarters country as recorded in the PharmaTek directory; 38 letters had no identified HQ and are excluded from the country breakdown.
- This analysis counts the volume and distribution of Warning Letters; it does not classify the underlying violations, and inclusion is not a judgement about any individual company.
Cite this report: PharmaTek Intelligence, “FDA Warning Letters to Drug Manufacturers: A 2008–2026 Analysis,” July 2026. https://pharmatek.co.uk/reports/fda-warning-letters
Screen any supplier against live FDA enforcement data
Search recalls, Warning Letters, and Form 483 observations across thousands of drug manufacturers and API suppliers.
See the directory